CD69 and acute myeloid leukemia: Although NK cell expression of the CD69 activation marker was increased in response to either therapy, only HMA/venetoclax treatment upregulated NK cell expression of activating DNAM-1 receptor, which was reduced in untreated AML patients compared to HDs.